Skip to content

To Assess the Mildness of a Cosmetic Cleanser in Healthy Participants Using the Forearm-Controlled Application Technique (FCAT)

A Clinical Study to Assess the Mildness of a Cosmetic Cleanser in Healthy Subjects Using the Forearm-Controlled Application Technique (FCAT)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03119688
Enrollment
50
Registered
2017-04-18
Start date
2017-05-08
Completion date
2017-05-26
Last updated
2019-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Care

Brief summary

The objective of this clinical study is to assess the relative mildness of a cosmetic facial cleanser in comparison to water through repeated application to the volar forearm using the FCAT wash procedure.

Detailed description

This is a test site randomized, examiner blinded, positive and negative-controlled, single-center; Forearm Controlled Application Technique clinical study in healthy participants to assess the mildness potential of a cosmetic facial cleansing product.

Interventions

OTHERTest Product

Micellar cleanser (0.09 ml)

OTHERPositive Control

Bar Soap (rubbed for 6 seconds to generate a lather)

OTHERReference Product

Sterile Water (0.09 ml)

OTHERNo Treatment

Unwashed area of the forearm

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. * Aged between 18 and 65 years inclusive. * Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination. * Intact skin at the proposed application site; volar forearm. * Clinical assessment for eligibility by a dermatologist to ensure participant is free of clinically relevant dermatological conditions. * Fitzpatrick phototype I to IV. * Trained examiner scores of zero for dryness and redness for each volar forearm at Screening visit (Visit 1) and each allocated test site on each forearm at Baseline visit. * Agreement to comply with the procedures and requirements of the study and to attend the scheduled assessment visits.

Exclusion criteria

* Women who are known to be pregnant or who are intending to become pregnant over the duration of the study. * Women who are breast-feeding * Any history of significant dermatological diseases or conditions or medical conditions known to alter skin appearance or physiologic response (e.g. diabetes,) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluation of the test site reaction. * Presence of open sores, pimples, or cysts at the application site. * Active dermatosis (local or disseminated) that might interfere with the results of the study. * Considered immune compromised. * History of diseases aggravated or triggered by ultraviolet radiation. * History of atopic dermatitis. * Participants with dermatographism. * Currently using any medication which in the opinion of the investigator, may affect the evaluation of the study product, or place the participant at undue risk. * Use of the following topical or systemic medications: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs, and corticosteroids upto 2 weeks before screening visit. * Oral or topical treatment with vitamin A acid and/or its derivatives up to 1 month before the screening visit. * Intention of being vaccinated during the study period or has been vaccinated within 3 weeks of the screening visit. * Currently receiving allergy injections, or received an allergy injection within 7 days prior to Visit 1, or expects to begin injections during study participation. * Previous history of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, cosmetics or medication. * Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. * Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit. * Previous participation in this study. * Recent history (within the last 5 years) of alcohol or other substance abuse. * Intense sunlight exposure or sun tanning sessions, including use of self-tanning products on the test areas up to 14 days before the Screening evaluation. * Intention of bathing (in the sea or pool), sauna, water sports, or activities that lead to intense sweating. * Any Participant who, in the judgment of the Investigator and Dermatologist, should not participate in the study. * Any skin marks on the test site that might interfere with the evaluation of possible skin reactions (e.g. pigmentation disorders, vascular malformations, scars, tattoos, excessive hair, numerous freckles). * Prisoner or involuntary incarcerated participant * Participant from an indigenous tribe. * An employee of the sponsor or the study site or members of their immediate family.

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Visual Assessment of Dryness at Day 5At Baseline and Day 5 (3 hours post last wash procedure)Skin dryness was assessed by a trained examiner according to following the scoring scale: 0 (No dryness); 1 (Patches of slight powederiness and occasional patches of small scales may be seen, distribution generalized.); 2 (Generalised slight powederiness, early cracking or occasional small lifting scales may be present); 3 (Generalised moderate powederiness and/or heavy cracking and lifting scales; 4 (Generalised heavy powederiness and/or heavy cracking and lifting scales); 5 (Generalised high cracking and lifting scales, eczematous change may be present, powederiness may be present but not prominent, may see bleeding crack); 6 (Generalised severe cracking, eczematous change may be present, bleeding cracks may be present, scale large may be beginning to disappear). Lower scores reflect less dry skin.

Secondary

MeasureTime frameDescription
Change From Baseline in Visual Assessment of Redness at Day 5At Baseline and Day 5 (3 hours post last wash procedure)Skin redness was assessed by a trained examiner according to following the scoring scale: 0 (No redness); 1(Barely detectable redness); 2(Slight redness); 3 (Moderate redness); 4 (Heavy or substantial redness); 5 (Extreme redness); 6 (Severe Redness). Lower scores reflect less skin redness.
Change From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4At Baseline and Day 2, 3, and 4 (3 hours post last wash procedure)Skin dryness was assessed by a trained examiner according to following the scoring scale: 0 (No dryness); 1 (Patches of slight powederiness and occasional patches of small scales may be seen, distribution generalized.); 2 (Generalised slight powederiness, early cracking or occasional small lifting scales may be present); 3 (Generalised moderate powederiness and/or heavy cracking and lifting scales; 4 (Generalised heavy powederiness and/or heavy cracking and lifting scales); 5 (Generalised high cracking and lifting scales, eczematous change may be present, powederiness may be present but not prominent, may see bleeding crack); 6 (Generalised severe cracking, eczematous change may be present, bleeding cracks may be present, scale large may be beginning to disappear). Lower scores reflect less dry skin.
Change From Baseline in Visual Assessment of Redness at Day 2, 3, and 4At Baseline and Day 2, 3, and 4 (3 hours post last wash procedure)Skin redness was assessed by a trained examiner according to following the scoring scale: 0 (No redness); 1(Barely detectable redness); 2(Slight redness); 3 (Moderate redness); 4 (Heavy or substantial redness); 5 (Extreme redness); 6 (Severe Redness). Lower scores reflect less skin redness.
Change From Baseline in Transepidermal Water Loss (TEWL) at Day 5At Baseline and Day 5 (3 hours post last wash procedure)TEWL was measured using Tewameter. TEWL measuring principle was based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belonged to the equilibration phase. The values of the last 10 sec were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function.
Change From Baseline in Skin Moisturisation at Day 5At Baseline and Day 5 (3 hours post last wash procedure)Corneometry was used to measure moisture content of stratum corneum using corneometer. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the gold conductors of the probe an electrical field was built which allowed the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content, the stratum corneum moisturisation can be measured. The Corneometer probe was placed in contact with the skin of the paarticipant's test site for 1-2 seconds per measurement. The Corneometer measurements were taken and an average (mean) reading was calculated for each site and time point. Corneometer values lower than 30 instrumental units (i.u.) represents very dry skin, while values between 30 und 50 i.u are typically for dry skin on the forearm. An increase in Corneometer values, therefore, corresponds to a skin-moisturising effect.

Countries

Brazil

Participant flow

Recruitment details

Participants were recruited from one center in Brazil.

Pre-assignment details

A total of 89 participants were screened, out of which 39 participants did not meet the study criteria. Remaining 50 participants were enrolled in the study, out of which 2 participants were not randomized to the study due to adverse events (AEs).

Participants by arm

ArmCount
Overall Participants
All participants enrolled in the study received all the study products and received at least 1 wash procedure. Each participant received 9 controlled wash applications over 5 days of test product (0.09 mL), positive control (soap bar) and negative control (0.09 mL) at each allocated test site. Therefore, each participant received a total of 27 applications of study products. Each wash procedure included a 10-second application of the test product, followed by a 90-second wait and a 15-second rinse-off with sterile water.
48
Total48

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event4

Baseline characteristics

CharacteristicOverall Participants
Age, Continuous39.1 Years
STANDARD_DEVIATION 13.69
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
8 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
39 Participants
Sex: Female, Male
Female
47 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
deaths
Total, all-cause mortality
0 / 480 / 480 / 480 / 480 / 48
other
Total, other adverse events
4 / 484 / 484 / 482 / 486 / 48
serious
Total, serious adverse events
0 / 480 / 480 / 480 / 480 / 48

Outcome results

Primary

Change From Baseline in Visual Assessment of Dryness at Day 5

Skin dryness was assessed by a trained examiner according to following the scoring scale: 0 (No dryness); 1 (Patches of slight powederiness and occasional patches of small scales may be seen, distribution generalized.); 2 (Generalised slight powederiness, early cracking or occasional small lifting scales may be present); 3 (Generalised moderate powederiness and/or heavy cracking and lifting scales; 4 (Generalised heavy powederiness and/or heavy cracking and lifting scales); 5 (Generalised high cracking and lifting scales, eczematous change may be present, powederiness may be present but not prominent, may see bleeding crack); 6 (Generalised severe cracking, eczematous change may be present, bleeding cracks may be present, scale large may be beginning to disappear). Lower scores reflect less dry skin.

Time frame: At Baseline and Day 5 (3 hours post last wash procedure)

Population: ITT population (N=48) was the primary population of analysis, which included all participants who were randomized and received at least one wash procedure, including sterile water, and had at least one post-baseline clinical assessment. Number of participants analyzed for this endpoint were part of the ITT population, evaluated on Day 5.

ArmMeasureValue (MEAN)Dispersion
TestChange From Baseline in Visual Assessment of Dryness at Day 50.48 Score on a scaleStandard Deviation 0.284
Positive ControlChange From Baseline in Visual Assessment of Dryness at Day 50.91 Score on a scaleStandard Deviation 0.291
Negative ControlChange From Baseline in Visual Assessment of Dryness at Day 50.56 Score on a scaleStandard Deviation 0.29
No TreatmentChange From Baseline in Visual Assessment of Dryness at Day 50.63 Score on a scaleStandard Deviation 0.307
Comparison: The null hypothesis (non-inferiority setting) is that the population mean dryness for Test minus Baxter Sterile Water (negative control) is at least 0.25.p-value: 0.176990% CI: [-0.1707, 0.0169]ANOVA
Comparison: The null hypothesis is that the difference in population mean dryness is zero.p-value: <0.000190% CI: [0.2565, 0.4441]ANOVA
Comparison: The null hypothesis is that the difference in population mean dryness is zero.p-value: <0.000190% CI: [0.3333, 0.5211]ANOVA
Comparison: The null hypothesis is that the difference in population mean dryness is zero.p-value: 0.251890% CI: [-0.0287, 0.1592]ANOVA
Secondary

Change From Baseline in Skin Moisturisation at Day 5

Corneometry was used to measure moisture content of stratum corneum using corneometer. The measuring principle was based on changes in the capacitance of the measuring head, functioning as a condensator. Between the gold conductors of the probe an electrical field was built which allowed the dielectricity of the stratum corneum to be measured. Because the dielectricity of the skin varies as a function of its water content, the stratum corneum moisturisation can be measured. The Corneometer probe was placed in contact with the skin of the paarticipant's test site for 1-2 seconds per measurement. The Corneometer measurements were taken and an average (mean) reading was calculated for each site and time point. Corneometer values lower than 30 instrumental units (i.u.) represents very dry skin, while values between 30 und 50 i.u are typically for dry skin on the forearm. An increase in Corneometer values, therefore, corresponds to a skin-moisturising effect.

Time frame: At Baseline and Day 5 (3 hours post last wash procedure)

Population: ITT population (N=48) was the primary population of analysis, which included all participants who were randomized and received at least one wash procedure, including sterile water, and had at least one post-baseline clinical assessment. Number of participants analyzed for this endpoint were part of the ITT population, evaluated on Day 5.

ArmMeasureValue (MEAN)Dispersion
TestChange From Baseline in Skin Moisturisation at Day 52.35 i.u.Standard Deviation 5.341
Positive ControlChange From Baseline in Skin Moisturisation at Day 5-4.57 i.u.Standard Deviation 5.368
Negative ControlChange From Baseline in Skin Moisturisation at Day 52.13 i.u.Standard Deviation 4.803
No TreatmentChange From Baseline in Skin Moisturisation at Day 50.34 i.u.Standard Deviation 3.729
Secondary

Change From Baseline in Transepidermal Water Loss (TEWL) at Day 5

TEWL was measured using Tewameter. TEWL measuring principle was based on water vapour gradient determination between two pairs of sensors placed at different distances perpendicularly to the skin. The probe was held in place on the skin for one measurement, for approximately 40 seconds (sec), to ensure that a stable value has been established. The first part of the measurement belonged to the equilibration phase. The values of the last 10 sec were averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function.

Time frame: At Baseline and Day 5 (3 hours post last wash procedure)

Population: ITT population (N=48) was the primary population of analysis, which included all participants who were randomized and received at least one wash procedure, including sterile water, and had at least one post-baseline clinical assessment. Number of participants analyzed for this endpoint were part of the ITT population, evaluated on Day 5.

ArmMeasureValue (MEAN)Dispersion
TestChange From Baseline in Transepidermal Water Loss (TEWL) at Day 50.91 g/m^2/hrStandard Deviation 2.118
Positive ControlChange From Baseline in Transepidermal Water Loss (TEWL) at Day 51.95 g/m^2/hrStandard Deviation 2.025
Negative ControlChange From Baseline in Transepidermal Water Loss (TEWL) at Day 50.94 g/m^2/hrStandard Deviation 1.714
No TreatmentChange From Baseline in Transepidermal Water Loss (TEWL) at Day 50.53 g/m^2/hrStandard Deviation 1.682
Secondary

Change From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4

Skin dryness was assessed by a trained examiner according to following the scoring scale: 0 (No dryness); 1 (Patches of slight powederiness and occasional patches of small scales may be seen, distribution generalized.); 2 (Generalised slight powederiness, early cracking or occasional small lifting scales may be present); 3 (Generalised moderate powederiness and/or heavy cracking and lifting scales; 4 (Generalised heavy powederiness and/or heavy cracking and lifting scales); 5 (Generalised high cracking and lifting scales, eczematous change may be present, powederiness may be present but not prominent, may see bleeding crack); 6 (Generalised severe cracking, eczematous change may be present, bleeding cracks may be present, scale large may be beginning to disappear). Lower scores reflect less dry skin.

Time frame: At Baseline and Day 2, 3, and 4 (3 hours post last wash procedure)

Population: ITT population (N=48) was the primary population of analysis, which included all participants who were randomized and received at least one wash procedure, including sterile water, and had at least one post-baseline clinical assessment.

ArmMeasureGroupValue (MEAN)Dispersion
TestChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 20.25 Score on a scaleStandard Deviation 0.253
TestChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 40.43 Score on a scaleStandard Deviation 0.255
TestChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 30.37 Score on a scaleStandard Deviation 0.248
Positive ControlChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 20.46 Score on a scaleStandard Deviation 0.307
Positive ControlChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 40.76 Score on a scaleStandard Deviation 0.314
Positive ControlChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 30.66 Score on a scaleStandard Deviation 0.298
Negative ControlChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 30.38 Score on a scaleStandard Deviation 0.285
Negative ControlChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 20.28 Score on a scaleStandard Deviation 0.251
Negative ControlChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 40.42 Score on a scaleStandard Deviation 0.24
No TreatmentChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 20.31 Score on a scaleStandard Deviation 0.265
No TreatmentChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 40.55 Score on a scaleStandard Deviation 0.302
No TreatmentChange From Baseline in Visual Assessment of Dryness at Day 2, 3, and 4Day 30.42 Score on a scaleStandard Deviation 0.26
Secondary

Change From Baseline in Visual Assessment of Redness at Day 2, 3, and 4

Skin redness was assessed by a trained examiner according to following the scoring scale: 0 (No redness); 1(Barely detectable redness); 2(Slight redness); 3 (Moderate redness); 4 (Heavy or substantial redness); 5 (Extreme redness); 6 (Severe Redness). Lower scores reflect less skin redness.

Time frame: At Baseline and Day 2, 3, and 4 (3 hours post last wash procedure)

Population: ITT population (N=48) was the primary population of analysis, which included all participants who were randomized and received at least one wash procedure, including sterile water, and had at least one post-baseline clinical assessment.

ArmMeasureGroupValue (MEAN)Dispersion
TestChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 40.00 Score on a scaleStandard Deviation 0
TestChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 20.06 Score on a scaleStandard Deviation 0.167
TestChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 30.00 Score on a scaleStandard Deviation 0
Positive ControlChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 30.00 Score on a scaleStandard Deviation 0
Positive ControlChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 20.05 Score on a scaleStandard Deviation 0.154
Positive ControlChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 40.01 Score on a scaleStandard Deviation 0.075
Negative ControlChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 40.00 Score on a scaleStandard Deviation 0
Negative ControlChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 20.01 Score on a scaleStandard Deviation 0.072
Negative ControlChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 30.00 Score on a scaleStandard Deviation 0
No TreatmentChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 30.00 Score on a scaleStandard Deviation 0
No TreatmentChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 20.01 Score on a scaleStandard Deviation 0.072
No TreatmentChange From Baseline in Visual Assessment of Redness at Day 2, 3, and 4Day 40.02 Score on a scaleStandard Deviation 0.151
Secondary

Change From Baseline in Visual Assessment of Redness at Day 5

Skin redness was assessed by a trained examiner according to following the scoring scale: 0 (No redness); 1(Barely detectable redness); 2(Slight redness); 3 (Moderate redness); 4 (Heavy or substantial redness); 5 (Extreme redness); 6 (Severe Redness). Lower scores reflect less skin redness.

Time frame: At Baseline and Day 5 (3 hours post last wash procedure)

Population: ITT population (N=48) was the primary population of analysis, which included all participants who were randomized and received at least one wash procedure, including sterile water, and had at least one post-baseline clinical assessment. Number of participants analyzed for this endpoint were part of the ITT population, evaluated on Day 5.

ArmMeasureValue (MEAN)Dispersion
TestChange From Baseline in Visual Assessment of Redness at Day 50.01 Score on a scaleStandard Deviation 0.075
Positive ControlChange From Baseline in Visual Assessment of Redness at Day 50.00 Score on a scaleStandard Deviation 0
Negative ControlChange From Baseline in Visual Assessment of Redness at Day 50.00 Score on a scaleStandard Deviation 0
No TreatmentChange From Baseline in Visual Assessment of Redness at Day 50.00 Score on a scaleStandard Deviation 0

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026